Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus LYBREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus LYBREL.
KELNOR vs LYBREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive